Advanced search

Showing result 1 - 5 of 44 swedish dissertations matching the above criteria.

  2. 1. Prognostic Markers in Diffuse Large B-cell Lymphoma : How Bad can it be

    Author : Gustaf Hedström; Gunilla Enblad; Francesco D'Amore; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; DLBCL; Survival; Mast cell; Microenvironment; MicroRNA; MDM2; Polymorphism; Age; Epidemiology; Oncology; Onkologi;

    Abstract : Diffuse large B-cell lymphoma (DLBCL), which is the most common type of lymphoma, is characterised by its aggressiveness and poor outcome without adequate treatment and also for its biological and clinical heterogeneity. It is therefore highly desirable to gain a more profound understanding of the underlying biology of the disease, as well as predictive factors for the guidance of treatment. READ MORE

  4. 2. Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma : with emphasis on comorbidity, toxicity and outcome

    Author : Charlott Mörth; Gunilla Enblad; Kristina Drott; Uppsala universitet; []
    Keywords : DLBCL; autoimmune disease; cardiac toxicity; neurotoxicity; EFS; OS; Medicinsk vetenskap; Medical Science;

    Abstract : Diffuse large B-cell lymphoma (DLBCL) is curable in around 70% when treated with standard immunochemotherapy R- CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). Treatment related toxicity affecting survivors is a clinical problem as well as comorbidities influencing the possibility to give adequate treatment. READ MORE

  5. 3. Potential New Drugs in Lymphoma

    Author : Maryam Delforoush; Gunilla Enblad; Mattias Berglund; Christina Drott; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; lymphoma; diffuse large B-cell lymphoma; DLBCL; picropodophyllin; PPP; J1; melflufen; prodrug; cancer therapeutics; alkylating agents; b-AP15; proteasome inhibitors; DUB inhibition; UCHL5; USP14;

    Abstract : Lymphomas are malignant tumours arising from cells in the lymphatic system. They are classified as B-cell lymphomas, T-cell lymphomas and Hodgkin lymphoma (HL). Of the B-cell lymphomas, one of the most common is diffuse large B-cell lymphoma (DLBCL). READ MORE

  6. 4. Diffuse large B-cell lymphoma - proteomic and metabolomic studies on prognosis and treatment failure

    Author : Martin Stenson; Göteborgs universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; DLBCL; prognostics; proteomics; metabolomics;

    Abstract : Abstract Background and aim: Every year almost 600 patients in Sweden are diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, and with immunochemotherapy, approximately 60 % are cured. Yet, for patients with primary refractory disease or early relapse, the prognosis is very poor. READ MORE

  7. 5. Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

    Author : Amal Abu Sabaa; Gunilla Enblad; Peter de Nully Brown; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; DLBCL; R-CHOP; EFS24; PEA; Biomarker; ELISA; TCL1A.;

    Abstract : The general aim of this thesis was to study the prognostic clinical and biological markers of Diffuse Large B-cell Lymphoma (DLBCL).Paper I: Utilizing population-based data for patients with DLBCL in Sweden, the study aimed to establish whether event free survival at 24 months (EFS24) was a reproducible milestone. READ MORE